Nuclear Medicine Equipment Market by Product (Imaging: PET, SPECT, Gamma; GM Counter, Dose Calibrator), Software (Image Management, PACS, Treatment, Analytic, Workflow), Therapy (Onco, Cardio, Neuro, Ortho), End User & Region - Global Forecasts to 2030

1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 STUDY SCOPE 35 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 35 1.3.2 INCLUSIONS AND EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 36 1.4 CURRENCY CONSIDERED 37 1.5 STAKEHOLDERS 37 2 RESEARCH METHODOLOGY 38 2.1 RESEARCH APPROACH 38 2.1.1 SECONDARY RESEARCH 38 2.1.1.1 Key data from secondary sources 39 2.1.2 PRIMARY RESEARCH 40 2.1.2.1 Primary sources 40 2.1.2.2 Key data from primary sources 41 2.1.2.3 Breakdown of primary interviews 41 2.1.2.4 Insights from primary experts 42 2.2 RESEARCH METHODOLOGY 42 2.3 MARKET SIZE ESTIMATION 43 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 48 2.5 MARKET SHARE ESTIMATION 48 2.6 RESEARCH ASSUMPTIONS 49 2.7 RESEARCH LIMITATIONS 49 2.8 RISK ASSESSMENT 49 3 EXECUTIVE SUMMARY 50 4 PREMIUM INSIGHTS 54 4.1 OVERVIEW OF NUCLEAR MEDICINE EQUIPMENT MARKET 54 4.2 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA 55 4.3 GEOGRAPHIC SNAPSHOT OF NUCLEAR MEDICINE EQUIPMENT MARKET 56 4.4 NUCLEAR MEDICINE EQUIPMENT MARKET: REGIONAL MIX 57 4.5 NUCLEAR MEDICINE EQUIPMENT MARKET: DEVELOPED VS. EMERGING MARKETS 57   5 MARKET OVERVIEW 58 5.1 INTRODUCTION 58 5.2 MARKET DYNAMICS 58 5.2.1 DRIVERS 60 5.2.1.1 Rapid expansion of theranostics 60 5.2.1.2 Technological advancements in hybrid imaging modalities 60 5.2.1.3 Favorable government support and expanding healthcare infrastructure 61 5.2.1.4 Advancements in radiotracers and radiopharmaceuticals 61 5.2.1.5 Integration of AI into nuclear medicine equipment 62 5.2.2 RESTRAINTS 62 5.2.2.1 Capital-intensive nature of equipment 62 5.2.2.2 Short half-life of radiopharmaceuticals 63 5.2.2.3 High maintenance and operational costs 63 5.2.2.4 Shortage of trained personnel 64 5.2.3 OPPORTUNITIES 64 5.2.3.1 Growing preference for personalized and precision medicine 64 5.2.3.2 Telemedicine and cloud-native platforms & mobile/remote imaging capabilities 65 5.2.4 CHALLENGES 65 5.2.4.1 Global isotope supply chain instability 65 5.2.4.2 Cybersecurity and data privacy issues in imaging IT 66 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66 5.4 INDUSTRY TRENDS 67 5.4.1 SHIFT TOWARD HYBRID AND MULTI-MODALITY IMAGING SYSTEMS 67 5.4.2 ADVANCEMENTS IN DETECTOR TECHNOLOGIES AND IMAGE QUALITY 68 5.4.3 GROWING DEMAND FOR COMPACT AND VERSATILE SYSTEMS 68 5.4.4 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND AUTOMATION 68 5.4.5 CONNECTIVITY AND CLOUD-ENABLED WORKFLOWS 68 5.5 PRICING ANALYSIS 68 5.5.1 INTRODUCTION 68 5.5.2 INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY KEY PLAYER 69 5.5.3 INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY REGION 70 5.5.4 AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE 71 5.5.5 PRICING MODELS 72 5.6 VALUE CHAIN ANALYSIS 73 5.7 ECOSYSTEM ANALYSIS 75 5.8 INVESTMENT AND FUNDING SCENARIO 78 5.9 TECHNOLOGY ANALYSIS 78 5.9.1 KEY TECHNOLOGIES 78 5.9.1.1 Hybrid imaging systems 78 5.9.1.2 Digital detection technology 78 5.9.1.3 Artificial Intelligence (AI) and advanced image reconstruction techniques 79 5.9.1.4 Time-of-Flight (TOF) technology 79 5.9.1.5 Solid-state detector technology 79 5.9.2 COMPLEMENTARY TECHNOLOGIES 79 5.9.2.1 Radiopharmaceutical development and theranostics 79 5.9.2.2 Advanced computing and big data analytics 80 5.9.2.3 Robotics and automated dose dispensing systems 80 5.9.3 ADJACENT TECHNOLOGIES 80 5.9.3.1 Magnetic Resonance Imaging (MRI) integration 80 5.9.3.2 Computed Tomography (CT) advancements 80 5.10 PATENT ANALYSIS 81 5.11 TRADE ANALYSIS 82 5.11.1 IMPORT DATA FOR HS CODE 901814 83 5.11.2 EXPORT DATA FOR HS CODE 901814 84 5.12 KEY CONFERENCES AND EVENTS, 2025–2026 84 5.13 CASE STUDY ANALYSIS 85 5.13.1 PRECISION IN NUCLEAR MEDICINE WITH NATIONAL STANDARD TRACEABILITY 85 5.13.2 MULTI-MODALITY IMAGE FUSION FOR IMPROVED DIAGNOSTICS 86 5.13.3 REMOTE CONSULTATION WITH CLOUD-BASED NUCLEAR MEDICINE ANALYSIS 86 5.14 TARIFF AND REGULATORY LANDSCAPE 87 5.14.1 TARIFF DATA FOR HS CODE 901814 87 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 5.14.3 REGULATORY ANALYSIS 90 5.15 PORTER’S FIVE FORCES ANALYSIS 94 5.15.1 BARGAINING POWER OF SUPPLIERS 96 5.15.2 BARGAINING POWER OF BUYERS 96 5.15.3 THREAT OF NEW ENTRANTS 96 5.15.4 THREAT OF SUBSTITUTES 96 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 96 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 97 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 97 5.16.2 BUYING CRITERIA 98 5.17 END-USER ANALYSIS 98 5.17.1 UNMET NEEDS 98 5.17.2 END-USER EXPECTATIONS 99 5.18 BUSINESS MODEL 100 5.18.1 DIRECT EQUIPMENT SALES MODEL 100 5.18.2 SERVICE AND MAINTENANCE CONTRACTS 100 5.18.3 PAY-PER-SCAN (OR PAY-PER-USE) MODEL 101 5.18.4 EQUIPMENT LEASING AND FINANCING SOLUTIONS 101 5.18.5 INTEGRATED SOLUTIONS AND MANAGED SERVICES 101 5.18.6 SOFTWARE AND DATA ANALYTICS SUBSCRIPTION 101 5.19 IMPACT OF AI/GEN AI 101 5.19.1 INTRODUCTION 101 5.19.2 MARKET POTENTIAL OF AI/GEN AI 102 5.19.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 103 5.19.3.1 AI-based low-dose PET image reconstruction 103 5.19.3.2 Dose-aware diffusion models for 3D low-dose PET 103 5.19.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 104 5.19.4.1 Medical image analysis software 104 5.19.4.2 Radiology information systems 104 5.19.4.3 Clinical decision support systems 105 5.19.5 USER READINESS AND IMPACT ASSESSMENT 105 5.19.5.1 User readiness 105 5.19.5.1.1 User A: Hospitals 105 5.19.5.1.2 User B: Diagnostic imaging centers 105 5.19.5.2 Impact assessment 106 5.19.5.2.1 User A: Hospitals 106 5.19.5.2.2 User B: Diagnostic imaging centers 106 5.20 IMPACT OF 2025 US TARIFF - OVERVIEW 107 5.20.1 INTRODUCTION 107 5.20.2 KEY TARIFF RATES 107 5.20.3 PRICE IMPACT ANALYSIS 108 5.20.3.1 Capital equipment (cyclotrons, PET/SPECT systems) 108 5.20.3.2 Gamma cameras 108 5.20.3.3 Key materials: semiconductors, detectors, shielding 108 5.20.3.4 Service parts, maintenance, and global supply chains 108 5.20.4 IMPACT ON COUNTRY/REGION 109 5.20.4.1 US 109 5.20.4.2 Europe 109 5.20.4.3 Asia Pacific 109 5.20.5 IMPACT ON END-USE INDUSTRIES 110 5.20.5.1 Hospitals 110 5.20.5.2 Diagnostic imaging centers 110 5.20.5.3 Cancer treatment centers 110 5.20.5.4 Other end users 111 5.20.6 CONCLUSION 111   6 NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE 112 6.1 INTRODUCTION 113 6.2 IMAGING MODALITIES 113 6.2.1 PET 115 6.2.1.1 Standalone PET 116 6.2.1.1.1 Increasing demand for cost-efficient, high-throughput oncological imaging to boost market 116 6.2.1.2 Hybrid PET 117 6.2.1.2.1 Ability to provide functional and anatomical information in single scan to aid growth 117 6.2.2 SPECT 118 6.2.2.1 Standalone SPECT 120 6.2.2.1.1 Wide use in thyroid studies, renal scans, and bone imaging to encourage growth 120 6.2.2.2 Hybrid SPECT 121 6.2.2.2.1 Need for improved diagnostic accuracy and clinical confidence to propel market 121 6.2.3 GAMMA/SCINTILLATION CAMERAS 122 6.2.3.1 Clinical versatility and lower cost to expedite growth 122 6.3 NON-IMAGING MODALITIES 123 6.3.1 GM COUNTERS 124 6.3.1.1 Ease of use, portability, and critical role in maintaining workplace safety to spur growth 124 6.3.2 DOSE CALIBRATORS 126 6.3.2.1 Increasing development in digital interfaces, automatic isotope recognition, and real-time data logging to bolster growth 126 6.3.3 PROBE COUNTING SYSTEMS 127 6.3.3.1 Technological advancements in probe counting systems to contribute to growth 127 6.3.4 GAMMA WELL COUNTERS 128 6.3.4.1 Growing use of gamma well counters in laboratory-based applications to propel market 128 6.3.5 OTHER NON-IMAGING MODALITIES 129 7 NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA 131 7.1 INTRODUCTION 132 7.2 ONCOLOGY 132 7.2.1 IMPROVEMENTS IN IMAGING ACCURACY AND TREATMENT PLANNING TO STIMULATE GROWTH 132 7.3 NEUROLOGY 134 7.3.1 ESCALATING GLOBAL BURDEN OF NEURODEGENERATIVE DISORDERS AND OTHER NEUROLOGICAL CONDITIONS TO AID GROWTH 134 7.4 CARDIOLOGY 135 7.4.1 PERSISTENT GLOBAL BURDEN OF CARDIOVASCULAR DISEASES TO FACILITATE GROWTH 135 7.5 ORTHOPEDICS 137 7.5.1 GROWING PREVALENCE OF DEGENERATIVE JOINT DISEASES, SPORTS INJURIES, AND OSTEOPOROSIS TO BOOST MARKET 137 7.6 THYROID 138 7.6.1 GLOBAL PREVALENCE OF HYPER- AND HYPOTHYROIDISM AND THYROID CANCER TO AUGMENT GROWTH 138 7.7 OTHER THERAPEUTIC AREAS 140 8 NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION 141 8.1 INTRODUCTION 142 8.2 2D 142 8.2.1 WIDE AVAILABILITY, EASE OF INTEGRATION, AND ESTABLISHED PRESENCE IN CLINICAL WORKFLOW TO AID GROWTH 142 8.3 3D 143 8.3.1 GROWING RELIANCE ON ADVANCED IMAGING TECHNOLOGIES TO FUEL MARKET 143 9 NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER 145 9.1 INTRODUCTION 146 9.2 HOSPITALS 146 9.2.1 CONTINUOUS TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH 146 9.3 DIAGNOSTIC IMAGING CENTERS 147 9.3.1 GROWING DEMAND FOR EARLY AND PRECISE DIAGNOSIS TO DRIVE MARKET 147 9.4 CANCER TREATMENT CENTERS 148 9.4.1 ESCALATING GLOBAL INCIDENCE OF CANCER TO PROMOTE GROWTH 148 9.5 OTHER END USERS 150 10 NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION 152 10.1 INTRODUCTION 153 10.2 NORTH AMERICA 154 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 154 10.2.2 US 159 10.2.2.1 Advancements in PET and SPECT equipment for personalized care to aid growth 159 10.2.3 CANADA 162 10.2.3.1 Increasing adoption of advanced imaging technologies to support growth 162 10.3 EUROPE 165 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 166 10.3.2 GERMANY 170 10.3.2.1 Increasing adoption of hybrid imaging systems to spur growth 170 10.3.3 UK 173 10.3.3.1 Favorable clinical guidelines supporting wider use of PET-CT to fuel market 173 10.3.4 FRANCE 176 10.3.4.1 Shift to hybrid imaging to accelerate growth 176 10.3.5 ITALY 179 10.3.5.1 Robust network of scanners to facilitate growth 179 10.3.6 SPAIN 182 10.3.6.1 Growing integration of cutting-edge technologies into clinical practice to propel market 182 10.3.7 SWEDEN 185 10.3.7.1 Rapid shift toward PET procedures to accelerate growth 185 10.3.8 REST OF EUROPE 188 10.4 ASIA PACIFIC 191 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 191 10.4.2 JAPAN 197 10.4.2.1 Ongoing innovations in equipment and growing reliance on nuclear imaging for accurate detection to drive market 197 10.4.3 CHINA 200 10.4.3.1 Rapid investments in medical infrastructure and technological advancements in image analysis to spur growth 200 10.4.4 INDIA 203 10.4.4.1 Substantial cancer and cardiovascular disease burden to encourage growth 203 10.4.5 SOUTH KOREA 206 10.4.5.1 Universal health coverage to bolster growth 206 10.4.6 AUSTRALIA 209 10.4.6.1 Strong diagnostic imaging network and widespread adoption of hybrid imaging technologies to contribute to growth 209 10.4.7 REST OF ASIA PACIFIC 212 10.5 MIDDLE EAST & AFRICA 215 10.5.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 216 10.5.2 GCC COUNTRIES 220 10.5.2.1 Growing healthcare needs and favorable government support to boost market 220 10.5.3 REST OF MIDDLE EAST & AFRICA 223 10.6 LATIN AMERICA 226 10.6.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 226 10.6.2 BRAZIL 230 10.6.2.1 Healthcare modernization efforts to accelerate growth 230 10.6.3 MEXICO 233 10.6.3.1 Expanding healthcare infrastructure to bolster growth 233 10.6.4 REST OF LATIN AMERICA 236   11 COMPETITIVE LANDSCAPE 240 11.1 OVERVIEW 240 11.2 KEY PLAYER STRATEGIES 240 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE EQUIPMENT MARKET 241 11.3 REVENUE ANALYSIS, 2020–2024 243 11.4 MARKET SHARE ANALYSIS, 2024 243 11.4.1 POSITRON EMISSION TOMOGRAPHY (PET) EQUIPMENT 247 11.4.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) EQUIPMENT 249 11.5 MARKET RANKING ANALYSIS 251 11.6 BRAND/PRODUCT COMPARISON 252 11.7 COMPANY VALUATION AND FINANCIAL METRICS 253 11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 254 11.8.1 STARS 254 11.8.2 EMERGING LEADERS 254 11.8.3 PERVASIVE PLAYERS 254 11.8.4 PARTICIPANTS 254 11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 256 11.8.5.1 Company footprint 256 11.8.5.2 Region footprint 257 11.8.5.3 System type footprint 258 11.8.5.4 Therapeutic area footprint 259 11.8.5.5 Dimension footprint 260 11.8.5.6 End-user footprint 261 11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 262 11.9.1 PROGRESSIVE COMPANIES 262 11.9.2 RESPONSIVE COMPANIES 262 11.9.3 DYNAMIC COMPANIES 262 11.9.4 STARTING BLOCKS 262 11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 264 11.9.5.1 Detailed list of key startups/SMEs 264 11.9.5.2 Competitive benchmarking of startups/SMEs 264 11.10 COMPETITIVE SCENARIO 265 11.10.1 PRODUCT LAUNCHES AND APPROVALS 265 11.10.2 DEALS 266 11.10.3 EXPANSIONS 267 11.10.4 OTHER DEVELOPMENTS 268   12 COMPANY PROFILES 269 12.1 KEY PLAYERS 269 12.1.1 GE HEALTHCARE 269 12.1.1.1 Business overview 269 12.1.1.2 Products offered 270 12.1.1.3 Recent developments 272 12.1.1.3.1 Product launches and approvals 272 12.1.1.3.2 Deals 273 12.1.1.3.3 Expansions 275 12.1.1.4 MnM view 276 12.1.1.4.1 Right to win 276 12.1.1.4.2 Strategic choices 276 12.1.1.4.3 Weaknesses and competitive threats 276 12.1.2 SIEMENS HEALTHINEERS AG 277 12.1.2.1 Business overview 277 12.1.2.2 Products offered 278 12.1.2.3 Recent developments 281 12.1.2.3.1 Product launches and approvals 281 12.1.2.3.2 Deals 282 12.1.2.4 MnM view 283 12.1.2.4.1 Right to win 283 12.1.2.4.2 Strategic choices 283 12.1.2.4.3 Weaknesses and competitive threats 283 12.1.3 KONINKLIJKE PHILIPS N.V. 285 12.1.3.1 Business overview 285 12.1.3.2 Products offered 286 12.1.3.3 Recent developments 288 12.1.3.3.1 Product launches and approvals 288 12.1.3.3.2 Deals 289 12.1.3.4 MnM view 289 12.1.3.4.1 Right to win 289 12.1.3.4.2 Strategic choices 290 12.1.3.4.3 Weaknesses and competitive threats 290 12.1.4 MIRION TECHNOLOGIES, INC. 291 12.1.4.1 Business overview 291 12.1.4.2 Products offered 292 12.1.4.3 Recent developments 294 12.1.4.3.1 Product launches and approvals 294 12.1.4.3.2 Deals 294 12.1.4.4 MnM view 295 12.1.4.4.1 Right to win 295 12.1.4.4.2 Strategic choices 295 12.1.4.4.3 Weaknesses and competitive threats 295 12.1.5 CANON MEDICAL SYSTEMS CORPORATION 296 12.1.5.1 Business overview 296 12.1.5.2 Products offered 297 12.1.5.3 Recent developments 298 12.1.5.3.1 Deals 298 12.1.5.4 MnM view 298 12.1.5.4.1 Right to win 298 12.1.5.4.2 Strategic choices 298 12.1.5.4.3 Weaknesses and competitive threats 299 12.1.6 HERMES MEDICAL SOLUTIONS 300 12.1.6.1 Business overview 300 12.1.6.2 Products offered 300 12.1.6.3 Recent developments 301 12.1.6.3.1 Product launches and approvals 301 12.1.6.3.2 Deals 302 12.1.6.3.3 Other developments 303 12.1.7 DOSISOFT SA 304 12.1.7.1 Business overview 304 12.1.7.2 Products offered 304 12.1.7.3 Recent developments 305 12.1.7.3.1 Product launches and approvals 305 12.1.7.3.2 Deals 305 12.1.8 SEGAMI CORPORATION 306 12.1.8.1 Business overview 306 12.1.8.2 Products offered 306 12.1.9 WINKGEN MEDICAL SYSTEMS GMBH & CO. KG 307 12.1.9.1 Business overview 307 12.1.9.2 Products offered 307 12.1.9.3 Recent developments 308 12.1.9.3.1 Product launches and approvals 308 12.1.9.3.2 Deals 308 12.1.10 COMECER S.P.A. 309 12.1.10.1 Business overview 309 12.1.10.2 Products offered 310 12.1.10.3 Recent developments 312 12.1.10.3.1 Product launches and approvals 312 12.1.10.3.2 Deals 312 12.1.10.3.3 Expansions 313 12.1.11 SYNTERMED INC. 314 12.1.11.1 Business overview 314 12.1.11.2 Products offered 314 12.1.11.3 Recent developments 315 12.1.11.3.1 Deals 315 12.1.12 ULTRASPECT INC. 316 12.1.12.1 Business overview 316 12.1.12.2 Products offered 316 12.1.13 LABLOGIC SYSTEMS LTD. 317 12.1.13.1 Business overview 317 12.1.13.2 Products offered 318 12.1.13.3 Recent developments 320 12.1.13.3.1 Product launches and approvals 320 12.1.13.3.2 Deals 320 12.1.13.3.3 Expansions 321 12.1.14 MEDISO LTD. 322 12.1.14.1 Business overview 322 12.1.14.2 Products offered 323 12.1.14.3 Recent developments 324 12.1.14.3.1 Product launches and approvals 324 12.1.15 CATALYST MEDTECH 325 12.1.15.1 Business overview 325 12.1.15.2 Products offered 325 12.1.15.3 Recent developments 326 12.1.15.3.1 Deals 326 12.1.15.3.2 Other developments 327 12.1.16 LEMER PAX 328 12.1.16.1 Business overview 328 12.1.16.2 Products offered 328 12.1.16.3 Recent developments 329 12.1.16.3.1 Product launches and approvals 329 12.1.16.3.2 Deals 329 12.1.17 SPECTRUM DYNAMICS MEDICAL 331 12.1.17.1 Business overview 331 12.1.17.2 Products offered 331 12.1.17.3 Recent developments 332 12.1.17.3.1 Product launches and approvals 332 12.1.17.3.2 Deals 332 12.1.18 NEUSOFT MEDICAL SYSTEMS CO., LTD. 333 12.1.18.1 Business overview 333 12.1.18.2 Recent developments 335 12.1.18.2.1 Product launches and approvals 335 12.1.18.2.2 Deals 335   12.1.19 BRAINLAB SE 336 12.1.19.1 Business overview 336 12.1.19.2 Products offered 336 12.1.19.3 Recent developments 337 12.1.19.3.1 Product launches and approvals 337 12.1.19.3.2 Deals 338 12.1.20 MIRADA MEDICAL 339 12.1.20.1 Business overview 339 12.1.20.2 Products offered 339 12.1.20.3 Recent developments 340 12.1.20.3.1 Product launches and approvals 340 12.1.20.3.2 Deals 341 12.2 OTHER PLAYERS 342 12.2.1 TRASIS 342 12.2.2 SOFIE 343 12.2.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE 344 12.2.4 POSITRIGO AG 345 12.2.5 PAIRE 346 13 APPENDIX 347 13.1 DISCUSSION GUIDE 347 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 352 13.3 CUSTOMIZATION OPTIONS 354 13.4 RELATED REPORTS 354 13.5 AUTHOR DETAILS 355

TABLE 1 NUCLEAR MEDICINE EQUIPMENT MARKET: INCLUSIONS AND EXCLUSIONS 36 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2024 37 TABLE 3 NUCLEAR MEDICINE EQUIPMENT MARKET: RESEARCH ASSUMPTIONS 49 TABLE 4 NUCLEAR MEDICINE EQUIPMENT MARKET: RISK ASSESSMENT 49 TABLE 5 NUCLEAR MEDICINE EQUIPMENT MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 59 TABLE 6 INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY KEY PLAYER, 2024 (USD) 70 TABLE 7 INDICATIVE PRICE OF NUCLEAR MEDICINE EQUIPMENT, BY REGION, 2024 (USD) 71 TABLE 8 AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE, 2024 (USD) 71 TABLE 9 NUCLEAR MEDICINE EQUIPMENT MARKET: ROLE OF COMPANIES IN ECOSYSTEM 77 TABLE 10 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR NUCLEAR MEDICINE EQUIPMENT MARKET, 2025 81 TABLE 11 IMPORT DATA FOR HS CODE 901814, BY COUNTRY, 2020–2024 (USD THOUSAND) 83 TABLE 12 EXPORTS DATA FOR HS CODE 901814, BY COUNTRY, 2020–2024 (USD THOUSAND) 84 TABLE 13 NUCLEAR MEDICINE EQUIPMENT MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 84 TABLE 14 TARIFF DATA FOR HS CODE 901814 87 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 TABLE 18 REGULATORY STANDARDS IN NUCLEAR MEDICINE 90 TABLE 19 REGULATORY REQUIREMENTS IN NORTH AMERICA 91 TABLE 20 REGULATORY REQUIREMENTS IN EUROPE 92 TABLE 21 REGULATORY REQUIREMENTS IN ASIA PACIFIC 92 TABLE 22 REGULATORY REQUIREMENTS IN LATIN AMERICA 94 TABLE 23 REGULATORY REQUIREMENTS IN MIDDLE EAST & AFRICA 94 TABLE 24 NUCLEAR MEDICINE EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 95 TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 97 TABLE 26 KEY BUYING CRITERIA FOR END USERS 98 TABLE 27 UNMET NEEDS IN NUCLEAR MEDICINE EQUIPMENT MARKET 99 TABLE 28 END-USER EXPECTATIONS IN NUCLEAR MEDICINE EQUIPMENT MARKET 100 TABLE 29 US ADJUSTED RECIPROCAL TARIFF RATES 107 TABLE 30 NUCLEAR MEDICINE EQUIPMENT, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 113 TABLE 31 NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 114 TABLE 32 NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 33 NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (UNITS) 114 TABLE 34 PET EQUIPMENT OFFERED BY MAJOR PLAYERS 115 TABLE 35 NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 115 TABLE 36 NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 37 NUCLEAR MEDICINE EQUIPMENT MARKET FOR STANDALONE PET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 38 NUCLEAR MEDICINE EQUIPMENT MARKET FOR HYBRID PET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 39 SPECT EQUIPMENT OFFERED BY MAJOR PLAYERS 119 TABLE 40 NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 119 TABLE 41 NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 42 NUCLEAR MEDICINE EQUIPMENT MARKET FOR STANDALONE SPECT, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 43 NUCLEAR MEDICINE EQUIPMENT MARKET FOR HYBRID SPECT, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 44 GAMMA/SCINTILLATION CAMERAS OFFERED BY MAJOR PLAYERS 122 TABLE 45 NUCLEAR MEDICINE EQUIPMENT MARKET FOR GAMMA/SCINTILLATION CAMERAS, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 46 NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 124 TABLE 47 NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 48 GM COUNTERS OFFERED BY MAJOR PLAYERS 125 TABLE 49 NUCLEAR MEDICINE EQUIPMENT MARKET FOR GM COUNTERS, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 50 DOSE CALIBRATORS OFFERED BY MAJOR PLAYERS 126 TABLE 51 NUCLEAR MEDICINE EQUIPMENT MARKET FOR DOSE CALIBRATORS, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 52 PROBE COUNTING SYSTEMS OFFERED BY MAJOR PLAYERS 128 TABLE 53 NUCLEAR MEDICINE EQUIPMENT MARKET FOR PROBE COUNTING SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 54 GAMMA WELL COUNTERS OFFERED BY MAJOR PLAYERS 129 TABLE 55 NUCLEAR MEDICINE EQUIPMENT MARKET FOR GAMMA WELL COUNTERS, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 56 NUCLEAR MEDICINE EQUIPMENT MARKET FOR OTHER NON-IMAGING MODALITIES, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 57 NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 132 TABLE 58 NUCLEAR MEDICINE EQUIPMENT FOR ONCOLOGY OFFERED BY MAJOR PLAYERS 133 TABLE 59 NUCLEAR MEDICINE EQUIPMENT MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 60 NUCLEAR MEDICINE EQUIPMENT FOR NEUROLOGY OFFERED BY MAJOR PLAYERS 135 TABLE 61 NUCLEAR MEDICINE EQUIPMENT MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 62 NUCLEAR MEDICINE EQUIPMENT FOR CARDIOLOGY OFFERED BY MAJOR PLAYERS 136 TABLE 63 NUCLEAR MEDICINE EQUIPMENT MARKET FOR CARDIOLOGY, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 64 NUCLEAR MEDICINE EQUIPMENT FOR ORTHOPEDICS OFFERED BY MAJOR PLAYERS 138 TABLE 65 NUCLEAR MEDICINE EQUIPMENT MARKET FOR ORTHOPEDICS, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 66 NUCLEAR MEDICINE EQUIPMENT FOR THYROID OFFERED BY MAJOR PLAYERS 139 TABLE 67 NUCLEAR MEDICINE EQUIPMENT MARKET FOR THYROID, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 68 NUCLEAR MEDICINE EQUIPMENT MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 69 NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 142 TABLE 70 NUCLEAR MEDICINE 2D EQUIPMENT OFFERED BY MAJOR PLAYERS 142 TABLE 71 NUCLEAR MEDICINE 2D EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 72 NUCLEAR MEDICINE 3D EQUIPMENT OFFERED BY MAJOR PLAYERS 144 TABLE 73 NUCLEAR MEDICINE 3D EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 74 NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 146 TABLE 75 NUCLEAR MEDICINE EQUIPMENT FOR HOSPITALS OFFERED BY MAJOR PLAYERS 147 TABLE 76 NUCLEAR MEDICINE EQUIPMENT MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 77 NUCLEAR MEDICINE EQUIPMENT FOR DIAGNOSTIC IMAGING CENTERS OFFERED BY MAJOR PLAYERS 148 TABLE 78 NUCLEAR MEDICINE EQUIPMENT MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 79 NUCLEAR MEDICINE EQUIPMENT FOR CANCER TREATMENT CENTERS OFFERED BY MAJOR PLAYERS 149 TABLE 80 NUCLEAR MEDICINE EQUIPMENT MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 81 NUCLEAR MEDICINE EQUIPMENT FOR OTHER END USERS OFFERED BY MAJOR PLAYERS 151 TABLE 82 NUCLEAR MEDICINE EQUIPMENT MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 83 NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 84 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 155 TABLE 85 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 86 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 156 TABLE 87 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 88 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 89 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 90 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 91 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 158 TABLE 92 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 158 TABLE 93 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 158 TABLE 94 US: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 159 TABLE 95 US: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 96 US: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 97 US: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 98 US: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 99 US: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 161 TABLE 100 US: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 161 TABLE 101 US: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 162 TABLE 102 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 163 TABLE 103 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 104 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 105 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 164 TABLE 106 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 164 TABLE 107 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 164 TABLE 108 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 165 TABLE 109 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 165 TABLE 110 EUROPE: KEY MACROECONOMIC INDICATORS 166 TABLE 111 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 112 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 167 TABLE 113 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 114 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 115 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 116 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE 2023–2030 (USD MILLION) 168 TABLE 117 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 169 TABLE 118 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 169 TABLE 119 EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 169 TABLE 120 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 170 TABLE 121 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 122 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 123 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 124 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 125 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 172 TABLE 126 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 172 TABLE 127 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 172 TABLE 128 UK: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 173 TABLE 129 UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 173 TABLE 130 UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 131 UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 132 UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 133 UK: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 175 TABLE 134 UK: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 175 TABLE 135 UK: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 175 TABLE 136 FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 176 TABLE 137 FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 138 FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 139 FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 140 FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 141 FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 178 TABLE 142 FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 178 TABLE 143 FRANCE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 178 TABLE 144 ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 179 TABLE 145 ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 146 ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 147 ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 148 ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 149 ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 181 TABLE 150 ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 181 TABLE 151 ITALY: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 181 TABLE 152 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 182 TABLE 153 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 182 TABLE 154 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 155 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 156 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 157 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 184 TABLE 158 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 184 TABLE 159 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 184 TABLE 160 SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 185 TABLE 161 SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 162 SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 163 SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 164 SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 165 SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 187 TABLE 166 SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 187 TABLE 167 SWEDEN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 187 TABLE 168 REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 188 TABLE 169 REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 170 REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 171 REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 172 REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 173 REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 190 TABLE 174 REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 190 TABLE 175 REST OF EUROPE: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 176 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 192 TABLE 177 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 178 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 194 TABLE 179 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 180 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 181 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 182 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 183 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 196 TABLE 184 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 196 TABLE 185 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 196 TABLE 186 JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 197 TABLE 187 JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 188 JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 189 JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 190 JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 191 JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 199 TABLE 192 JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 199 TABLE 193 JAPAN: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 199 TABLE 194 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 200 TABLE 195 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 196 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 197 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 198 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 199 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 202 TABLE 200 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 203 TABLE 201 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 203 TABLE 202 INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 204 TABLE 203 INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 204 INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 205 INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 206 INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 207 INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 205 TABLE 208 INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 206 TABLE 209 INDIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 210 SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 207 TABLE 211 SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE 2023–2030 (USD MILLION) 207 TABLE 212 SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 207 TABLE 213 SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 214 SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 215 SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 208 TABLE 216 SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 209 TABLE 217 SOUTH KOREA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 209 TABLE 218 AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 210 TABLE 219 AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 220 AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 221 AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 222 AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 223 AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 211 TABLE 224 AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 212 TABLE 225 AUSTRALIA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 212 TABLE 226 REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 213 TABLE 227 REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 228 REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 229 REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 230 REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 231 REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 214 TABLE 232 REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 215 TABLE 233 REST OF ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 215 TABLE 234 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 216 TABLE 235 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 217 TABLE 236 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 217 TABLE 237 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 238 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 239 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 240 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 241 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 219 TABLE 242 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 219 TABLE 243 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 219 TABLE 244 GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 220 TABLE 245 GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 246 GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 247 GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 248 GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 249 GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 222 TABLE 250 GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 222 TABLE 251 GCC COUNTRIES: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 223 TABLE 252 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 223 TABLE 253 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 254 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 255 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 256 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 257 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 225 TABLE 258 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 225 TABLE 259 REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 260 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 227 TABLE 261 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 227 TABLE 262 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 227 TABLE 263 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 264 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 265 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 266 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 267 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 229 TABLE 268 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 229 TABLE 269 LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 270 BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 230 TABLE 271 BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 272 BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 273 BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 274 BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 275 BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 232 TABLE 276 BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 232 TABLE 277 BRAZIL: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 233 TABLE 278 MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 234 TABLE 279 MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 280 MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 281 MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 282 MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE 2023–2030 (USD MILLION) 235 TABLE 283 MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 235 TABLE 284 MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 236 TABLE 285 MEXICO: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 236 TABLE 286 REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2023–2030 (USD MILLION) 237 TABLE 287 REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 288 REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR SPECT, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 289 REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 290 REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR NON-IMAGING MODALITIES, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 291 REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 238 TABLE 292 REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2023–2030 (USD MILLION) 239 TABLE 293 REST OF LATIN AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2023–2030 (USD MILLION) 239 TABLE 294 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE EQUIPMENT MARKET, JANUARY 2022–JUNE 2025 241 TABLE 295 NUCLEAR MEDICINE EQUIPMENT MARKET: DEGREE OF COMPETITION 245 TABLE 296 POSITRON EMISSION TOMOGRAPHY (PET) EQUIPMENT MARKET: DEGREE OF COMPETITION 247 TABLE 297 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) EQUIPMENT MARKET: DEGREE OF COMPETITION 249 TABLE 298 NUCLEAR MEDICINE EQUIPMENT MARKET: REGION FOOTPRINT 257 TABLE 299 NUCLEAR MEDICINE EQUIPMENT MARKET: SYSTEM TYPE FOOTPRINT 258 TABLE 300 NUCLEAR MEDICINE EQUIPMENT MARKET: THERAPEUTIC AREA FOOTPRINT 259 TABLE 301 NUCLEAR MEDICINE EQUIPMENT MARKET: DIMENSION FOOTPRINT 260 TABLE 302 NUCLEAR MEDICINE EQUIPMENT MARKET: END-USER FOOTPRINT 261 TABLE 303 NUCLEAR MEDICINE EQUIPMENT MARKET: DETAILED LIST OF KEY STARTUPS/SMES 264 TABLE 304 NUCLEAR MEDICINE EQUIPMENT MARKET: COMPETITIVE BENCHMARKING OF SMES/STARTUPS 264 TABLE 305 NUCLEAR MEDICINE EQUIPMENT MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 265 TABLE 306 NUCLEAR MEDICINE EQUIPMENT MARKET: DEALS, JANUARY 2022–JUNE 2025 266 TABLE 307 NUCLEAR MEDICINE EQUIPMENT MARKET: EXPANSIONS, JANUARY 2022–JUNE 2025 267 TABLE 308 NUCLEAR MEDICINE EQUIPMENT MARKET: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 268 TABLE 309 GE HEALTHCARE: COMPANY OVERVIEW 269 TABLE 310 GE HEALTHCARE: PRODUCTS OFFERED 270 TABLE 311 GE HEALTHCARE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 272 TABLE 312 GE HEALTHCARE: DEALS, JANUARY 2022–JUNE 2025 273 TABLE 313 GE HEALTHCARE: EXPANSIONS, JANUARY 2022–JUNE 2025 275 TABLE 314 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 277 TABLE 315 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 278 TABLE 316 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 281 TABLE 317 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–JUNE 2025 282 TABLE 318 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 285 TABLE 319 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 286 TABLE 320 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 288 TABLE 321 KONINKLIJKE PHILIPS N.V: DEALS, JANUARY 2022–JUNE 2025 289 TABLE 322 MIRION TECHNOLOGIES, INC.: COMPANY OVERVIEW 291 TABLE 323 MIRION TECHNOLOGIES, INC.: PRODUCTS OFFERED 292 TABLE 324 MIRION TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 294 TABLE 325 MIRION TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JUNE 2025 294 TABLE 326 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW 296 TABLE 327 CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED 297 TABLE 328 CANON MEDICAL SYSTEMS CORPORATION: DEALS, JANUARY 2022–JUNE 2025 298 TABLE 329 HERMES MEDICAL SOLUTIONS: COMPANY OVERVIEW 300 TABLE 330 HERMES MEDICAL SOLUTIONS: PRODUCTS OFFERED 300 TABLE 331 HERMES MEDICAL SOLUTIONS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 301 TABLE 332 HERMES MEDICAL SOLUTIONS: DEALS, JANUARY 2022–JUNE 2025 302 TABLE 333 HERMES MEDICAL SOLUTIONS: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 303 TABLE 334 DOSISOFT SA: COMPANY OVERVIEW 304 TABLE 335 DOSISOFT SA: PRODUCTS OFFERED 304 TABLE 336 DOSISOFT SA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 305 TABLE 337 DOSISOFT SA: DEALS, JANUARY 2022–JUNE 2025 305 TABLE 338 SEGAMI CORPORATION: COMPANY OVERVIEW 306 TABLE 339 SEGAMI CORPORATION: PRODUCTS OFFERED 306 TABLE 340 WINKGEN MEDICAL SYSTEMS GMBH & CO. KG: COMPANY OVERVIEW 307 TABLE 341 WINKGEN MEDICAL SYSTEMS GMBH & CO. KG: PRODUCTS OFFERED 307 TABLE 342 WINKGEN MEDICAL SYSTEMS GMBH & CO. KG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 308 TABLE 343 WINKGEN MEDICAL SYSTEMS GMBH & CO. KG: DEALS, JANUARY 2022–JUNE 2025 308 TABLE 344 COMECER S.P.A.: COMPANY OVERVIEW 309 TABLE 345 COMECER S.P.A.: PRODUCTS OFFERED 310 TABLE 346 COMECER S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 312 TABLE 347 COMECER S.P.A.: DEALS, JANUARY 2022–JUNE 2025 312 TABLE 348 COMECER S.P.A.: EXPANSIONS, JANUARY 2022–JUNE 2025 313 TABLE 349 SYNTERMED INC.: COMPANY OVERVIEW 314 TABLE 350 SYNTERMED INC.: PRODUCTS OFFERED 314 TABLE 351 SYNTERMED INC.: DEALS, JANUARY 2022–JUNE 2025 315 TABLE 352 ULTRASPECT INC.: PRODUCTS OFFERED 316 TABLE 353 LABLOGIC SYSTEMS LTD.: COMPANY OVERVIEW 317 TABLE 354 LABLOGIC SYSTEMS LTD.: PRODUCTS OFFERED 318 TABLE 355 LABLOGIC SYSTEMS LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 320 TABLE 356 LABLOGIC SYSTEMS LTD.: DEALS, JANUARY 2022–JUNE 2025 320 TABLE 357 LABLOGIC SYSTEMS LTD.: EXPANSIONS, JANUARY 2022–JUNE 2025 321 TABLE 358 MEDISO LTD.: COMPANY OVERVIEW 322 TABLE 359 MEDISO LTD.: PRODUCTS OFFERED 323 TABLE 360 MEDISO LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 324 TABLE 361 CATALYST MEDTECH: COMPANY OVERVIEW 325 TABLE 362 CATALYST MEDTECH: PRODUCTS OFFERED 325 TABLE 363 CATALYST MEDTECH: DEALS, JANUARY 2022–JUNE 2025 326 TABLE 364 CATALYST MEDTECH: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 327 TABLE 365 LEMER PAX: COMPANY OVERVIEW 328 TABLE 366 LEMER PAX: PRODUCTS OFFERED 328 TABLE 367 LEMER PAX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 329 TABLE 368 LEMER PAX: DEALS, JANUARY 2022–JUNE 2025 329 TABLE 369 SPECTRUM DYNAMICS MEDICAL: COMPANY OVERVIEW 331 TABLE 370 SPECTRUM DYNAMICS MEDICAL: PRODUCTS OFFERED 331 TABLE 371 SPECTRUM DYNAMICS MEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 332 TABLE 372 SPECTRUM DYNAMICS MEDICAL: DEALS, JANUARY 2022–JUNE 2025 332 TABLE 373 NEUSOFT MEDICAL SYSTEMS CO., LTD.: COMPANY OVERVIEW 333 TABLE 374 NEUSOFT MEDICAL SYSTEMS CO., LTD.: PRODUCTS OFFERED 334 TABLE 375 NEUSOFT MEDICAL SYSTEMS CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 335 TABLE 376 NEUSOFT MEDICAL SYSTEMS CO., LTD.: DEALS, JANUARY 2022–JUNE 2025 335 TABLE 377 BRAINLAB SE: COMPANY OVERVIEW 336 TABLE 378 BRAINLAB SE: PRODUCTS OFFERED 336 TABLE 379 BRAINLAB SE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 337 TABLE 380 BRAINLAB SE: DEALS, JANUARY 2022–JUNE 2025 338 TABLE 381 MIRADA MEDICAL: COMPANY OVERVIEW 339 TABLE 382 MIRADA MEDICAL: PRODUCTS OFFERED 339 TABLE 383 MIRADA MEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 340 TABLE 384 MIRADA MEDICAL: DEALS, JANUARY 2022–JUNE 2025 341 TABLE 385 TRASIS: COMPANY OVERVIEW 342 TABLE 386 SOFIE: COMPANY OVERVIEW 343 TABLE 387 ITM ISOTOPE TECHNOLOGIES MUNICH SE: COMPANY OVERVIEW 344 TABLE 388 POSITRIGO AG: COMPANY OVERVIEW 345 TABLE 389 PAIRE: COMPANY OVERVIEW 346 FIGURE 1 NUCLEAR MEDICINE EQUIPMENT MARKET SEGMENTATION AND REGIONAL SCOPE 35 FIGURE 2 RESEARCH DESIGN 38 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41 FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 43 FIGURE 5 BOTTOM-UP APPROACH 44 FIGURE 6 TOP-DOWN APPROACH 45 FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS 46 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46 FIGURE 9 DATA TRIANGULATION METHODOLOGY 48 FIGURE 10 NUCLEAR MEDICINE EQUIPMENT MARKET, BY SYSTEM TYPE, 2025 VS. 2030 (USD MILLION) 50 FIGURE 11 NUCLEAR MEDICINE EQUIPMENT MARKET, BY DIMENSION, 2025 VS. 2030 (USD MILLION) 51 FIGURE 12 NUCLEAR MEDICINE EQUIPMENT MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 51 FIGURE 13 NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 52 FIGURE 14 NUCLEAR MEDICINE EQUIPMENT MARKET: REGIONAL SNAPSHOT 52 FIGURE 15 GROWING ADOPTION OF ADVANCED IMAGING MODALITIES AND EXPANSION OF THERANOSTICS TO DRIVE MARKET 54 FIGURE 16 ONCOLOGY SEGMENT AND JAPAN LED ASIA PACIFIC MARKET IN 2024 55 FIGURE 17 INDIA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 56 FIGURE 18 ASIA PACIFIC TO DOMINATE MARKET DURING FORECAST PERIOD 57 FIGURE 19 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 57 FIGURE 20 NUCLEAR MEDICINE EQUIPMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58 FIGURE 21 REVENUE SHIFT AND NEW REVENUE POCKETS IN NUCLEAR MEDICINE EQUIPMENT MARKET 67 FIGURE 22 AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE, 2024 (USD) 72 FIGURE 23 NUCLEAR MEDICINE EQUIPMENT MARKET: VALUE CHAIN ANALYSIS 75 FIGURE 24 NUCLEAR MEDICINE EQUIPMENT MARKET: ECOSYSTEM ANALYSIS 76 FIGURE 25 INVESTMENT AND FUNDING SCENARIO, 2015–2025 78 FIGURE 26 NUCLEAR MEDICINE EQUIPMENT MARKET: PATENT ANALYSIS, 2015–2025 82 FIGURE 27 NUCLEAR MEDICINE EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 95 FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 97 FIGURE 29 KEY BUYING CRITERIA FOR END USERS 98 FIGURE 30 MARKET POTENTIAL OF AI/GEN AI ON NUCLEAR MEDICINE EQUIPMENT ACROSS INDUSTRIES 102 FIGURE 31 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 104 FIGURE 32 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET SNAPSHOT, 2024 155 FIGURE 33 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET SNAPSHOT, 2024 193 FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE EQUIPMENT MARKET, 2020–2024 243 FIGURE 35 NUCLEAR MEDICINE EQUIPMENT MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 244 FIGURE 36 POSITRON EMISSION TOMOGRAPHY (PET) EQUIPMENT MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 247 FIGURE 37 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) EQUIPMENT MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 249 FIGURE 38 MARKET RANKING ANALYSIS OF KEY PLAYERS, 2024 251 FIGURE 39 NUCLEAR MEDICINE EQUIPMENT MARKET: BRAND/PRODUCT COMPARISON 252 FIGURE 40 EV/EBITDA OF KEY VENDORS 253 FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA 253 FIGURE 42 NUCLEAR MEDICINE EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 255 FIGURE 43 NUCLEAR MEDICINE EQUIPMENT MARKET: COMPANY FOOTPRINT 256 FIGURE 44 NUCLEAR MEDICINE EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 263 FIGURE 45 GE HEALTHCARE: COMPANY SNAPSHOT (2024) 270 FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 278 FIGURE 47 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024) 286 FIGURE 48 MIRION TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 292 FIGURE 49 CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2024) 297 FIGURE 50 NEUSOFT MEDICAL SYSTEMS CO., LTD.: COMPANY SNAPSHOT (2024) 334